Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Regeneron Pharmaceuticals and Sanofi presented promising new data for Libtayo® (cemiplimab) at the ESMO Virtual Congress 2020. Key highlights include late-breaking oral presentations on Libtayo's efficacy as a monotherapy for first-line advanced non-small cell lung cancer (NSCLC) and locally advanced basal cell carcinoma (BCC) in patients resistant to hedgehog inhibitors. The trials show Libtayo's potential to improve treatment outcomes in challenging cancers, supporting regulatory submissions in the U.S. and EU.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the New England Journal of Medicine published positive Phase 3 trial results for evinacumab in patients with homozygous familial hypercholesterolemia (HoFH). This investigational drug significantly reduced LDL cholesterol levels by 49% when added to standard therapies, especially in patients with low or no LDL-receptor activity. Evinacumab is under FDA Priority Review, with a decision expected by February 11, 2021, addressing a critical need for effective treatment in HoFH patients.
On August 19, 2020, Regeneron and Roche announced a collaboration to develop, manufacture, and distribute REGN-COV2, Regeneron's antibody cocktail for COVID-19. This partnership aims to increase production capacity by over 350%, significantly boosting the availability of doses for patients both in the U.S. and globally. REGN-COV2 is currently undergoing Phase 2/3 trials for treatment and Phase 3 trials for prevention. The companies are committed to sharing distribution responsibilities, with Regeneron handling U.S. sales and Roche focusing on international markets.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced the FDA's acceptance for Priority Review of its Biologics License Application (BLA) for evinacumab, targeting patients with homozygous familial hypercholesterolemia (HoFH). HoFH affects approximately 1,300 patients in the U.S., many of whom do not achieve optimal LDL-C levels with existing therapies. Evinacumab is designed to block angiopoietin-like 3 (ANGPTL3) to lower LDL-C. The FDA's target action date is February 11, 2021, and the drug has previously received Breakthrough Therapy designation.
Regeneron Pharmaceuticals announced the pricing of its underwritten offering of $1.250 billion in senior unsecured notes due 2030 with a 1.750% interest rate, and $750 million in notes due 2050 with a 2.800% interest rate. The issuance is expected to close around August 12, 2020. The funds will be used primarily to repay outstanding loans related to a stock repurchase from Sanofi and for general corporate purposes. The offering will support Regeneron's financial stability as it continues its drug development efforts.
Regeneron Pharmaceuticals reported a 24% revenue increase to $1.95 billion in Q2 2020, driven by strong sales of EYLEA and Dupixent. EYLEA's U.S. net sales were $1.11 billion, while Dupixent's global sales reached $945 million. GAAP diluted EPS stood at $7.61. The company initiated Phase 2 and 3 trials for REGN-COV2, targeting COVID-19. It also received FDA approval for Dupixent in children aged 6-11 with atopic dermatitis. Regeneron's balance sheet remains robust, positioning it for long-term growth amid operational challenges presented by the pandemic.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Society for Science & the Public announced winners of the Regeneron Science Talent Search 2020, awarding over $1.8 million in prizes to young innovators. Lillian Petersen won the top prize of $250,000 for her tool predicting crop yields, addressing food insecurity. Other notable projects included machine learning algorithms and eco-friendly industrial burners, showcasing youth contributions to science. The competition highlighted the importance of research in solving global challenges.
Regeneron Pharmaceuticals (NASDAQ: REGN) awarded $1.8 million to finalists of the 2020 Regeneron Science Talent Search, recognizing outstanding research by high school seniors. The top award of $250,000 went to Lillian Petersen from New Mexico for her tool predicting harvests, addressing food insecurity. Other notable projects include machine learning algorithms and eco-friendly gas burners. The competition, held virtually for the first time due to the pandemic, fosters scientific innovation among youth and has historically produced renowned science leaders.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced that BARDA has agreed to procure its investigational Ebola treatment, REGN-EB3, as part of national health emergency preparedness. REGN-EB3, currently under FDA Priority Review with a decision due by October 25, 2020, is expected to generate approximately $10 million in 2021 and an average of $67 million annually from 2022 to 2026 if approved. This follows promising results from the PALM trial, demonstrating superior efficacy in preventing Ebola-related deaths compared to existing treatments.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
